📊 CELUW Key Takeaways
Investment Thesis
Celularity is in critical financial distress with negative stockholders' equity of -$20.1M, liabilities exceeding assets by $20.1M, and severe liquidity constraints (0.16x current ratio). Despite 138% revenue growth, the company is burning cash at an unsustainable rate (-$8.3M FCF) with massive operating losses (-$39.2M) that dwarf gross profits, indicating fundamental business model challenges in its pharmaceutical operations.
CELUW Strengths
- Strong revenue growth of 138% year-over-year showing market demand
- Positive gross margin of 30.1% indicating viable unit economics at the product level
- Improved diluted EPS by 76% YoY despite continued losses, suggesting cost structure improvements
CELUW Risks
- Negative stockholders' equity of -$20.1M indicates technical insolvency and imminent need for capital restructuring or dilutive financing
- Critical liquidity crisis with only $120K cash against $134.3M liabilities and 0.16x current ratio, unable to fund operations or debt obligations
- Operating losses of -$39.2M far exceed gross profits, signaling unsustainable R&D, SG&A, and operating expenses despite revenue scaling
- Negative free cash flow of -$8.3M with -37% FCF margin indicates cash burn model is not sustainable without external funding
- $35.7M long-term debt burden with zero interest coverage capability given operating losses
Key Metrics to Watch
- Cash balance and runway until insolvency without additional financing
- Path to operating profitability and timeline to positive operating cash flow
- Debt restructuring plans or additional capital raises and dilution impact
- Revenue growth sustainability and gross margin maintenance as company scales
CELUW Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CELUW Profitability Ratios
CELUW vs Healthcare Sector
How Celularity Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CELUW Balance Sheet & Liquidity
CELUW 5-Year Financial Trend
5-Year Trend Summary: Celularity Inc's revenue has grown significantly by 154% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.02 indicates the company is currently unprofitable.
CELUW Growth Metrics (YoY)
CELUW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.3M | -$6.5M | $-0.73 |
| Q2 2025 | $5.7M | -$6.5M | $-0.30 |
| Q1 2025 | $11.4M | -$19.8M | $-0.84 |
| Q3 2024 | $3.8M | -$16.1M | $-0.73 |
| Q2 2024 | $2.9M | -$6.5M | $-0.30 |
| Q1 2024 | $3.9M | -$22.0M | $-1.03 |
| Q3 2023 | $3.8M | $4.8M | $0.03 |
| Q2 2023 | $2.9M | -$15.0M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CELUW Capital Allocation
CELUW SEC Filings
Access official SEC EDGAR filings for Celularity Inc (CIK: 0001752828)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CELUW
What is the AI rating for CELUW?
Celularity Inc (CELUW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CELUW's key strengths?
Strong revenue growth of 138% year-over-year showing market demand. Positive gross margin of 30.1% indicating viable unit economics at the product level.
What are the risks of investing in CELUW?
Negative stockholders' equity of -$20.1M indicates technical insolvency and imminent need for capital restructuring or dilutive financing. Critical liquidity crisis with only $120K cash against $134.3M liabilities and 0.16x current ratio, unable to fund operations or debt obligations.
What is CELUW's revenue and growth?
Celularity Inc reported revenue of $22.4M.
Does CELUW pay dividends?
Celularity Inc does not currently pay dividends.
Where can I find CELUW SEC filings?
Official SEC filings for Celularity Inc (CIK: 0001752828) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CELUW's EPS?
Celularity Inc has a diluted EPS of $-2.74.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.